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Abstract 
BACKGROUND: Parkinson's disease is one of the most common neurological diseases. Pathogenesis of the 
disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The 
precursor to dopamine, which crosses the protective blood-brain barrier, is the amino acid 3, 4-dihydroxy-L-
phenylalanine – levodopa, L-DOPA. The investigational drug is a pharmaceutical composition, containing L-DOPA 
as an active substance, which is distributed in a polymer matrix based on a biodegradable copolymer of 
lactic/glycolic acids. 
AIM: This work aimed to study the main pharmacokinetic parameters for the drug "L-DOPA – PC, nasal drops" 
and comparator drugs "L-DOPA in oil", "L-DOPA – PC in purified water", reference product – tablets "Madopar 
125".  
METHODS: To increase the bioavailability of the active substance L-DOPA, a new route of administration was 
used for the first time – nasal administration. Pharmacokinetics of the innovative drug with the intranasal route of 
administration was investigated in rabbits. The L-DOPA concentration in blood plasma was determined by high-
performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).  
RESULTS: Bioavailability of the drug – nasal drops were 244.4% compared with the drug "Madopar 125". 
CONCLUSION: Assay procedure for the determination of L-DOPA in animal blood plasma using liquid 
chromatography with tandem mass-selective detection (HPLC-MS/MS) was developed and validated. 
 
 
 
 
 
 
 
 
Introduction 
 
Parkinson's disease is a slowly progressing 
socially significant chronic neurological disease, 
characteristic of the older age group [1], refers to the 
degenerative diseases of the extrapyramidal motor 
system. The cause of the disease is progressive 
destruction and death of neurons that produce 
neurotransmitter dopamine [2], primarily in the black 
substance, as well as in other parts of the central 
nervous system. Insufficient production of dopamine 
leads to the activating influence of basal ganglia on 
the cerebral cortex. Leading symptoms are muscle 
rigidity, hypokinesia, tremor, postural instability. 
The innovative drug L-DOPA-PC, nasal 
drops, is an original pharmaceutical composition 
containing L-DOPA (3, 4-dihydroxy-L-phenylalanine, 
levodopa) as an active ingredient, distributed in the 
polymer matrix based on a biodegradable copolymer 
of lactic/glycolic acids (polylactide glycolide, PLGA 
50/50) [3]. 
L-DOPA’s mechanism of action is well studied 
and described in the literature [4], [5], [6], [7], [8]. L-
DOPA eliminates hypokinesia, rigidity, tremor, 
dysphagia, salivation. L-DOPA is an amino acid, an 
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immediate metabolic predecessor of dopamine, which 
unlike dopamine is able to cross the blood-brain 
barrier and compensate dopamine deficiency in the 
brain that underlies many clinical manifestations of 
Parkinson's disease. L-Dopa is captured by the 
endings of remaining dopaminergic nigrostriatal 
neurons, undergoes decarboxylation in them, turns 
into dopamine, which is released into the synaptic 
cleft, thus maintaining an adequate functional state of 
the neurons of the striatum and other basal ganglia. 
Modern scientists’ efforts are concentrated on 
medical drugs application frequency decreasing, 
preserving their efficiency [9], [10]. Nasal delivery 
method is one of the most promising. The most 
important feature of the medical products intranasal 
delivery is the opportunity to penetrate them directly 
into the central nervous system without entering the 
blood circulatory system. The medical products 
transportation from the nasal cavity to the central 
nervous system is implemented without the mucous 
participation. It is done using an extracellular tract 
through the epithelial barrier in the course trigeminal 
and olfactory nerves. It was earlier believed that all L-
dopa is entirely utilised in the sympathetic nerves 
ends and does not get out in the extracellular space. 
Nevertheless, rather, an important part of L-dopa 
leaves sympathetic nerves and arrives in the arterial 
and venous system, which supplies extremities, head, 
heart, adrenal glands and intestines with the blood 
[11]. 
To increase the bioavailability of the active 
substance L-DOPA, we used the nasal route of 
administration of the drug [4]. This work aimed to 
study the main pharmacokinetic parameters for the 
drug "L-DOPA – PC, nasal drops" and comparator 
drugs "L-DOPA in oil", "L-DOPA – PC in purified 
water", reference product – tablets "Madopar 125". 
 
 
Material and Methods 
 
"L-DOPA-PC nasal drops" was compared 
with: 
1. L-DOPA (3.75% of levodopa 
substance) in oil. 
2. L-DOPA – PC (3.75% of levodopa 
substance) in purified water. 
3.  "Madopar 125", dispersible tablets, 
(levodopa content-100 mg). Composition: levodopa 
100 mg, benserazide hydrochloride 28.5 mg. 
Excipients: anhydrous citric acid; corn starch pre-
gelatinized; microcrystalline cellulose; magnesium 
stearate. The tablet was dispersed in 10 ml of purified 
water and administered orally as a suspension 
through a feeding tube. 
The study was conducted on 24 male rabbits 
weighing 2900-3200 g. The animals were divided into 
4 groups of 6 rabbits each. Groups 1-3 administered 
the drug intra-nasally; the volume of administration 
was not more than 200 μl. Group 4 received the drug 
through oesophagal atraumatic bougie; the volume of 
administration was not more than 0,5 ml. The dose of 
administration for L-DOPA was 2.5 mg/kg. Blood 
samples were taken at the following time points: 0, 
0.08, 0,16, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36, 48 h. Five 
ml of blood was taken from the ear vein. The design of 
the study is given in Table 1. 
Table 1: Scheme of intranasal and oral administration of drugs 
based on L-DOPA 
Name of the 
administered 
sample 
Group of animals 
Group 1 Group 2 Group 3 Group 4 
Nasal oil drops 
based on L-
DOPA-PC 
Levodopa 
suspension in 
olive oil 
L-DOPA-PC 
suspension in 
purified water 
Tablets 
"Madopar 125" 
Content of 
Levodopa (L-
DOPA) 
5.0 % 3.75 % 3.75 % 100 mg 
Route of 
administration 
nasally orally 
Rate of 
application 
once once once once 
L-DOPA dose 2.5 mg/kg 2.5 mg/kg 2.5 mg/kg 2.5 mg/kg 
 
There are many L-DOPA research methods in 
various assay samples (HPLC-UV, HPLC-MS/MS and 
others). Method HPLC-UV is suitable for the 
determination of L-DOPA in dosage form [12]. HPLC-
MS/MS is used for pharmacokinetic studies owing to 
increased selectivity for the substance [11]. To 
improve the quality of the study, the method HPLC-
MS/MS was chosen. 
Determination of L-DOPA concentration in 
blood plasma was performed by high-performance 
liquid chromatography with tandem mass 
spectrometry (HPLC-MS/MS). Equipment used for the 
study – tandem quadrupole mass spectrometric 
detector, Shimadzu, manufactured in Japan; liquid 
chromatograph LC-30 Nexera, Shimadzu, Japan. 
Statistical data processing was carried out 
using Statistica 12.0 software. 
 
 
Results 
 
Four preparations of different compositions 
were obtained for the study; they contained the amino 
acid (3,4-dihydroxy-L-phenylalanine, levodopa, L-
DOPA) as an active ingredient. 
All the blood plasma samples obtained were 
analysed by HPLC-MS/MS. During the development 
of the assay procedure of the analyte understudy, a 
mass spectrum of L-DOPA was obtained. The mass 
spectrum was obtained in the full scan mode of 
fragment ions in the range of mass-to-charge ratios 
from 100 m/z to 500 m/z. Based on the data obtained, 
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characteristic ion transitions for the analyte under 
study were determined. The mass spectrum of L-
DOPA is shown in Figure 1. 
 
Figure 1: Mass spectrum of L-DOPA 
 
Typical results of L-DOPA concentration 
determination are shown in Figure 2. 
 
Figure 2: Mass chromatograms of L-DOPA in the blood plasma of 
rabbits after a single intranasal administration of levodopa 
suspension in olive oil (2), sample №1 
 
Figure 3 shows pharmacokinetic profiles of L-
Dopa in the blood of rabbits, in linear coordinates, 
after a single administration of the drugs "L-Dopa-PC 
nasal drops", "L-DOPA in oil", "L-DOPA-PC in purified 
water" and "Madopar 125" capsules. 
 
Figure 3: Graph of averaged pharmacokinetic profiles (in linear 
coordinates) for L-DOPA (observation from 0 to 48 hours) 
The main pharmacokinetic parameters are 
presented in Table 2. 
Table 2: Pharmacokinetic parameters calculated from averaged 
data 
Group Parameter T½ Tmax, 
h 
Cmax, 
ng/ml 
AUC0→48, 
ng × h/ml 
AUC 0-∞ 
ng × h/ml 
MRT, 
h 
Сmax/AUC0→t Сmax/AUC0→
∞ 
K el (h
-1
) 
(1) Mean 15.39 0.25 18.2 181.88 231.64 27.3 0.1002 0.0787 0.0452 
Gmean 15.38 0.25 18.1 180.75 230.91 27.3 0.1005 0.0787 0.0451 
Median 15.06 0.25 18.0 175.27 229.30 26.3 0.1026 0.0794 0.0460 
Min 14.53 0.25 15.5 167.81 214.83 25.6 0.0891 0.0721 0.0395 
Max 17.54 0.25 20.3 203.94 254.75 34.5 0.1073 0.0848 0.0477 
SD 1.09 0.00 1.7 13.76 16.52 3.5 0.0068 0.0051 0.0029 
(2) Mean 10.92 0.25 32.31 135.53 159.32 20.19 0.2383 0.2027 0.0636 
Gmean 10.91 0.25 32.16 135.24 159.09 20.12 0.2378 0.2022 0.0635 
Median 11.06 0.25 31.54 134.51 158.05 20.89 0.2426 0.2088 0.0627 
Min 10.12 0.25 28.21 124.73 149.54 17.23 0.2167 0.1788 0.0614 
Max 11.29 0.25 37.02 152.75 171.45 21.70 0.2613 0.2172 0.0685 
SD 0.44 0.00 3.38 9.82 9.46 1.82 0.0169 0.0161 0.0027 
(3) Mean 15.99 0.25 12.08 100.36 131.22 29.00 0.1209 0.0927 0.0437 
Gmean 15.92 0.25 12.03 99.62 129.97 28.96 0.1208 0.0926 0.0435 
Median 15.24 0.25 12.12 98.19 129.16 28.41 0.1215 0.0935 0.0455 
Min 14.73 0.25 10.54 86.43 109.17 26.96 0.1104 0.0825 0.0357 
Max 19.39 0.25 14.01 126.96 169.87 31.76 0.1275 0.0983 0.0471 
SD 1.73 0.00 1.23 14.02 20.73 1.75 0.0058 0.0055 0.0041 
(4) Mean 3.25 2.00 19.28 87.52 94.68 5.00 0.2220 0.2048 0.2265 
Gmean 3.14 2.00 19.26 87.14 94.43 4.95 0.2210 0.2040 0.2204 
Median 2.96 2.00 19.07 89.33 93.46 4.80 0.2210 0.2082 0.2343 
Min 2.50 2.00 17.95 72.91 86.44 4.29 0.1937 0.1769 0.1323 
Max 5.24 2.00 20.73 95.70 104.80 6.47 0.2487 0.2338 0.2777 
SD 1.01 0.00 1.06 8.71 7.56 0.82 0.0225 0.0201 0.0520 
 
 
 
Discussion 
 
Comparative analysis of main 
pharmacokinetic parameters for the investigational 
drug "L-Dopa-PC nasal drops"(1) and "L-Dopa in 
oil"(2), "L-Dopa-PC in purified water"(3), "Madopar 
125" capsules (4) (table 3) showed that the studied 
drugs quickly enter systemic circulation, however, at 
different rates. 
Table 3: Relative bioavailability of L-Dopa-PC-based nasal oil 
drops [1] 
Name of the administered 
sample 
Group of animals 
Group 2 Group 3 Group 4 
L-Dopa 
suspension in 
olive oil 
L-Dopa-PC 
suspension in 
purified water 
"Madopar 125", 
capsules 
Dosage 2.5 mg/kg 2.5 mg/kg 2.5 mg/kg 
RELATIVE BIOAVAILABILITY 
Group 1  
L-DOPA – PC based nasal oil 
drops 
Dosage - 2.5 mg/kg 
145.2 % 176.3 % 244.4 % 
 
Difference between L-DOPA absorption rate 
values (Cmax/AUC0t) for investigational drugs (1), 
(2), (3) and (4) is statistically-valid and for (1) was 
(0.1002 ± 0.0068) h
-1
, for (2) – (0.2383 ± 0.0169) h
-1
, 
for (3) – (0.1209 ± 0.0058) h
-1 
, for (4) – (0.2220 ± 
0.0225) h
-1
, and the individual variance of values is 
insignificant - CV was 22-23%. Time to reach 
maximum L-DOPA concentration (Tmax) for (1), (2), 
(3) was 0.25 h on average, which indicates that there 
were no significant differences in the time of reaching 
maximum concentration (Tmax) between the studied 
drugs. For the drug (4) time to reach maximum L-
DOPA concentration was 2 hours due to the oral route 
of administration, which shows a significant difference 
in the time to reach the maximum concentration 
(Tmax) between the studied drugs (1) and (4).  
100 150 200 250 300 350 400 450 m/z
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Inten. (x10,000)
425.3
323.9
178.1
252.0
133.1
442.2206.3
285.1
296.2 368.1 396.1
160.0
231.4
186.2
117.0 381.3
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The average maximum concentration of L-
DOPA, determined in the blood plasma of rabbits 
(Сmах), was for the drug (1) – (18.23 ± 1.68) ng/ml, 
for (3) – (12.08 ± 1.23) ng/ml, for (4) – (19.28 ± 1.06) 
ng/ml and (2) – (32.31 ± 3.38) ng/ml. L-Dopa is then 
slowly excreted from the body and after 48 hours it is 
still found in the blood plasma of rabbits after 
administration of drugs (1), (2) and (3), but after oral 
administration of the drug (4) after 12 hours L-Dopa is 
not detected. The results of the Student's test for Ln 
(Cmax) for the values between and within the groups 
(1-2) (t = -16.8105 at p < 0.05000), (1-3) (t = 10.80150 
for p < 0.05000), showed a statistically significant 
difference between groups (1) and (2), (1) and (3). 
The results of the Student's test for Ln (Cmax) for the 
values between and within the groups (1-4) (t = 
1.74050 at p < 0.05000) showed that there was no 
statistically significant difference between the groups. 
Analysis of the main parameter characterising 
the degree and rate of bioavailability of the active 
substance (L-DOPA) from the dosage form – the area 
under the pharmacokinetic curve (AUC0t) indicates 
a significant variability of this value. The average 
value of AUC0t for the drug (1) was (181.88 ± 
13.76) ng/ml×h, for (2) – (135.53 ± 9.82) ng/ml×h, for 
(3) – (100.36 ± 14.02) ng/ml × h, for (4) – (87.52 ± 
8.71) ng/ml × h. The average value of AUC0∞ for 
the drug (1) was (231.39 ± 16.52) ng/ml × h, for (3) – 
(131.22 ± 20.73) ng/ml × h, for (2) – (159.32 ± 
9.46) ng/ml × h, for (4) – (94.68 ± 7.56) ng/ml × h. The 
results of the Student's test for Ln (AUC0t) for the 
values between and within the groups: (1-2) (t = 
17.83326 at p < 0.05000), (1-3) (t = 9.041106 at p < 
0.05000) (1-4) (t = 18.05994 for p < 0.05000) showed 
that there is a statistically significant difference 
between groups. 
As can be seen from Table 3, the relative 
bioavailability of the drug "L-DOPA–PC nasal drops " 
(1) relative to the drug "L-DOPA in oil" (2) was 
145.2%. The relative bioavailability of the drug "L-
DOPA-PC nasal drops"(1) relative to the drug "L-
DOPA-PC in purified water" (3) was 176.3%. The 
relative bioavailability of the drug "L-DOPA-PC nasal 
drops"(1) relative to the drug "Madopar 125" (4) was 
244.4%. 
Parkinson's disease is the most frequent 
neurodegenerative disease after Alzheimer's disease 
[13], [14]. The disease is common in occurrence. 
Disease prevalence varies from 120 to 180 cases per 
100 thousand of the population; the number of 
patients increases significantly among the older age 
group. The prevalence per 100,000 population for the 
different age groups: 41 for the 40-49 age group; 107 
for the 50-59 age group; 173 for the 55-64 age group; 
428 for the 60-66 age group; 425 for the 65-74 age 
group; 1087 for the 70-79 age group; and 1903 for the 
age group over 80 years [15]. The average age of 
disease onset is 65.3 ± 2.6 years. The incidence in 
men is higher than in women [16]. No significant racial 
differences in the morbidity patterns were found [2]. 
A new method of administering nanoparticles, 
containing levodopa, allows rapid delivery of the 
dopamine neurotransmitter precursor to the brain 
cells. The most important feature of intranasal 
administration of drugs is the possibility of their 
penetration directly into the central nervous system. 
Transport of drugs from the nasal cavity to the central 
nervous system is performed without the involvement 
of the mucosa, extracellularly along the trigeminal and 
olfactory nerves. Within 10-15 minutes chemical 
agents administered intranasally are found in the 
brain. Drugs penetrate the brain only from the 
olfactory region, where there is a possibility of extra - 
and intracellular penetration of drugs through the 
epithelial barrier and getting not into the bloodstream, 
but directly to meninges. 
The study showed that the use of nasal 
delivery method improves pharmacokinetic 
parameters of the drug in comparison with oral 
administration. All the above mentioned allowed to 
increase the time of drug presence in the blood and, 
potentially, to use the drug in much smaller doses with 
a reduction in risk of toxic complications.  
In conclusion, a new form of the drug (oil-
based drops), containing the precursor of dopamine - 
L-DOPA, was developed for intranasal administration. 
Pharmacokinetic parameters of "L-DOPA – PC nasal 
drops" were studied in comparison with three other 
potentially active dosage forms, containing L-DOPA in 
the same concentrations as the study drug: "L-DOPA 
in oil", "L-DOPA-PC in purified water", "Madopar 125". 
Assay procedure for the determination of L-DOPA in 
animal blood plasma using liquid chromatography with 
tandem mass-selective detection (HPLC-MS/MS) was 
developed and validated.  
The relative bioavailability of the drug "L-
DOPA–PC nasal drops" relative to the drug "L-DOPA 
in oil" was 145.2%; relative to the drug "L-DOPA-PC 
in purified water" – 176.3%; relative to the drug 
"Madopar 125" – 244.4%. 
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